Drug Trial Radar · NCT07341152
A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Oct 6, 2025
Primary completion
Nov 17, 2025
Study completion Nov 17, 2025
Sponsor
- Lead sponsor
- Latigo BiotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, part-randomized, crossover study in 14 healthy participants to assess the PK and safety profile of an SDD formulation of LTG-001 and two crystalline LTG-001 Instant Release tablet formulations, one of which will also be assessed at a differing dose level.
Conditions
- Pain Management
Interventions
LTG-001 SDDDrug
LTG-001
LTG-001 Formulation A Prototype 1Drug
LTG-001
LTG-001 Formulation B Prototype 2Drug
LTG-001
LTG-001 Formulation B prototype 2Drug
LTG-001 High Dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the relative bioavailability of two different LTG-001 crystalline formulations (test) compared to the LTG-001 SDD formulation (reference) in the fasted state.Time frame: From enrollment to Period 4, Day 3 Discharge
- Determine the relative bioavailability of two different LTG-001 crystalline formulations (test) compared to the LTG-001 SDD formulation (reference) in the fasted stateTime frame: from enrollment to Period 4, Day 3 discharge
- Determine the relative bioavailability of two different LTG-001 crystalline formulations (test) compared to the LTG-001 SDD formulation (reference) in the fasted state.Time frame: from enrollment to Period 4, Day 3 discharge
- To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted state.Time frame: From Enrollment to Period 4, Day 3 discharge
- To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted stateTime frame: From enrollment to period 4, Day 3 Discharge
- To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted state.Time frame: enrollment to Period 4, Day 3 discharge
- To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted state.Time frame: from enrollment to Period 4, Day 3 discharge
- To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted state.Time frame: from enrollment to Period 4, Day 3 discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences - Miami, Inc
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.